New Stock Issuance - The stock code 300277 (Hai Lian Xun) has a subscription period for acquisition rights from November 12 to November 18, 2025[1] - Stock code 688353 (Hua Sheng Lithium) reported severe abnormal fluctuations on November 11, 2025[1] - Stock code 603122 (He Fu China) has an announcement dated November 8, 2025[1] Trading Alerts - Stock code 601888 (China Zhong Mian) has an announcement dated November 12, 2025[1] - Stock code 600537 (Yi Jing Guang Dian) has an announcement dated November 12, 2025[1] - Stock code 688028 (Wo Er De) has an announcement dated November 12, 2025[1] Abnormal Fluctuations - Stock code 600815 (Xia Gong Co.) reported abnormal fluctuations on November 6, 2025[2] - Stock code 603557 (ST Qi Bu) reported abnormal fluctuations on November 7, 2025[3] - Stock code 002478 (Chang Bao Co.) reported abnormal fluctuations on November 7, 2025[3]

Market Overview - On November 11, the Shanghai Composite Index fell by 0.39%, while the total margin balance in the market reached 2505.298 billion yuan, an increase of 3.882 billion yuan compared to the previous trading day [1] - The margin balance in the Shanghai Stock Exchange was 1275.565 billion yuan, up by 3.043 billion yuan; in the Shenzhen Stock Exchange, it was 1221.835 billion yuan, up by 0.852 billion yuan; and in the Beijing Stock Exchange, it was 7.899 billion yuan, down by 0.014 billion yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 18 sectors saw an increase in margin balances, with the banking sector leading with an increase of 0.423 billion yuan, followed by retail and agriculture sectors with increases of 0.359 billion yuan and 0.347 billion yuan, respectively [1] Stock Performance - A total of 1822 stocks experienced an increase in margin balances, accounting for 48.66% of the market, with 314 stocks seeing an increase of over 5% [1] - The stock with the highest increase in margin balance was Reet Technology, with a latest margin balance of 9.2716 million yuan, reflecting a 78.19% increase from the previous trading day, and its stock price rose by 0.79% [1] - Other notable stocks with significant margin balance increases included Jindike and Lusi Co., with increases of 59.04% and 50.08%, respectively [1] Top Gainers and Losers - Among the top 20 stocks with the highest margin balance increases, the average increase in stock prices was 6.13%, with notable gainers including Huanlejia, Jindike, and Juhua Technology, each rising by 19.99% [2] - Conversely, the stocks with the largest declines included Haima Automobile, Huadian Technology, and Liujin Technology, with declines of 1.97%, 1.88%, and 1.15%, respectively [2] Margin Balance Decrease - In contrast, 1922 stocks saw a decrease in margin balances, with 225 stocks experiencing a decline of over 5% [4] - The stock with the largest decrease in margin balance was Zhongcheng Consulting, with a latest margin balance of 1.3765 million yuan, down by 34.42% from the previous trading day [5] - Other stocks with significant declines included Meibang Technology and Sanwei Equipment, with decreases of 32.91% and 28.11%, respectively [5]

Group 1 - The stock of Jindike (688670) closed at 24.97 yuan on November 11, reaching the daily limit with a trading volume of 3.10 billion yuan and a turnover rate of 10.90% [2] - The stock was listed on the trading board due to a price increase of 15% at the close of the day [2] - The top five trading departments accounted for a total transaction amount of 1.02 billion yuan, with a net sell of 2093.03 million yuan [2] Group 2 - The main capital inflow for the stock was 4268.43 million yuan throughout the day [3] - The leading buying department was Dongfang Caifu Securities, with a purchase amount of 1076.31 million yuan [3] - The top selling department was Kaiyuan Securities, with a selling amount of 2010.57 million yuan [3]

Core Viewpoint - Jindike experienced a significant stock price increase, closing at 24.97 yuan per share, up 19.99%, marking its second consecutive trading limit up, with related flu concept stocks also rising [1] Company Overview - Jindike's main business includes research and production in biotechnology, particularly in the development of vaccines and related biological products [1] - The company is actively advancing its research projects to meet market demands, as evidenced by its ongoing Phase III clinical trials for the quadrivalent influenza virus split vaccine for children [1] Financial Performance - In the third quarter, Jindike reported a total R&D expenditure of 17.93 million yuan, which accounted for 25.21% of its operating revenue [1] - The increase in R&D expenses is primarily attributed to the Phase III clinical trials for the quadrivalent influenza virus split vaccine for children, indicating a year-on-year rise in R&D investment [1]

江苏金迪克生物技术股份有限公司关于董事辞职、选举职工代表董事及选举董事会 提名委员会委员的公告 江苏金迪克生物技术股份有限公司（以下简称"公司"）董事会于近日收到董事夏建国先生提交的辞职报 告，夏建国先生因公司治理结构调整原因申请辞去公司第二届董事会董事、董事会提名委员会委员职 务，辞去上述职务后，夏建国先生将继续在公司担任副总经理职务。根据《中华人民共和国公司法》 《上海证券交易所科创板股票上市规则》及《公司章程》的相关规定，夏建国先生的辞职报告自送达董 事会之日起生效。 2025年11月11日，公司召开了第七次职工代表大会，审议通过了《关于选举公司第二届董事会职工代表 董事的议案》，同意选举夏建国先生为公司第二届董事会职工代表董事，任期自本次职工代表大会审议 通过之日起至公司第二届董事会任期届满之日止。 同日，公司召开了第二届董事会第十五次会议，审议通过了《关于选举董事会提名委员会委员的议 案》，同意选举夏建国先生为公司第二届董事会提名委员会委员，任期自本次董事会审议通过之日起至 公司第二届董事会任期届满之日止。具体情况如下： 一、董事离任的情况 月 日召开第七次职工代表大会，经到会职工代表充分讨论，取得 ...

江苏金迪克生物技术股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日以通讯方式召开第二届董事会第十五次会议，审议通过了《关于聘任总经理 的议案》《关于选举董事会审计委员会委员的议案》，具体情况如下： 一、聘任总经理的情况 经公司董事长余军先生提名，公司董事会提名委员会审核通过，董事会同 意聘任张良斌先生为公司总经理，任期自本次董事会会议审议通过之日起至第 二届董事会届满之日止。张良斌先生简历详见附件。 张良斌先生具备履行总经理职责所需要的工作经验和专业知识，其任职资 格符合《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》等法 律法规以及《江苏金迪克生物技术股份有限公司章程》中有关任职资格的规定， 不存在不得担任高级管理人员的情形。 二、调整审计委员会委员的情况 根据中国证券监督管理委员会颁布的《上市公司独立董事管理办法》等有 关规定，审计委员会成员应当为不在上市公司担任高级管理人员的董事。公司 董事会于近日收到了董事会审计委员会委员张良斌先生提交的辞职报告，张良 斌先生因公司治理结构调整原因申请辞去第二届董事会审计委员会委员职务， 辞去上述职务后，张良斌先生将继续在公司担任董事、 ...

《关于江苏金迪克生物技术股份有限公司 会军: 2 /2 P+ 2 2 张良斌: l 日期：2025 年 11 月 11 日 . 致,江苏金迪克生物技术股份有限公司; 贵公司发出的《关于江苏金迪克生物技术股份有限公司股 票异常波动的询证函》已收悉,经本人认真自查核实,现回复 如下: 特此回复。 一、 截止目前,本人不存在涉及贵公司的应披露而未披露的重 大信息: 二、 截至目前，本人不存在处于筹划阶段的涉及贵公司的重大 事项,包括但不限于重大资产重组、股份发行、收购、债 务重组、业务重组、资产剥离、资产注入、股份回购、股 权激励、破产重组、重大业务合作、引进战略投资者等重 大事项: 三、 在本次股票交易异常波动期间, 本人不存在买卖贵公司股 票的情形。 (本页无正文,为《<关于江苏金迪克生物技术股份有限公司股 票异常波动的询证函>的回函》签字页 ) 股票异常波动的询证函》的回函 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-032 江苏金迪克生物技术股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海市锦天城律师事务所委派律师现场对本次股东大会进行了见证，并出具 了法律意见书。 二、 议案审议情况 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 11 日 （二） 股东大会召开的地点：江苏省泰州市郁金路 12 号公司行政楼一号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 34 | | --- | --- | | 普通股股东人数 | 34 | | 2、出席会议的股东所持有的表决权数量 | 86,975,757 | | 普通股股东所持有表决权数量 | 86,975,757 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 70.5972 | ...

Group 1 - The company announced the appointment of Mr. Zhang Liangbin as the new General Manager, effective from the date of the board meeting approval until the end of the second board term [1] - Mr. Zhang Liangbin resigned from his position as a member of the Audit Committee due to adjustments in the company's governance structure, but will continue to serve as a director and General Manager [1] - The board approved the election of Mr. Nie Shenqian as a member of the Audit Committee for the second board [1] Group 2 - The company's revenue composition for the year 2024 is 100% from biopharmaceuticals [1] - The current market capitalization of the company is 3.1 billion yuan [2]

格隆汇11月11日丨金迪克(688670.SH)公布，经公司董事长余军先生提名，公司董事会提名委员会审核 通过，董事会同意聘任张良斌先生为公司总经理，任期自本次董事会会议审议通过之日起至第二届董事 会届满之日止。 ...